glp-1 receptor agonist use and risk of suicide death therapy may reduce suicidal ideation for adolescents with obesity Benefit-Risk Assessment of GLP-1 Receptor
Description
American Diabetes Association, 79th Scientific Sessions 2019
Treatment usually starts at a low dose to minimise nausea, then increases gradually over several weeks
Research Evidence Comparison# Retatrutide Research# Phase 1 : First-in-human study established safety and pharmacokinetics Phase 2 (n=338) : Published in NEJM (2023), demonstrated dose-dependent weight loss up to 24.2% at 48 weeks with 12 mg dose
outcomes depend on protocol adherence Form: Medication, nutritional guidance, behavioral support, and ongoing monitoring Best for: Patients seeking long-term, sustainable results with professional oversight rather than medication alone A medically supervised weight loss program is not just a prescription
If you have Type 2 diabetes, cardiovascular disease, or sleep apnea alongside obesity, your provider should document those conditions prominently
